An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.

@article{Kelly2011AnAC,
  title={An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.},
  author={R. Kelly and Dian L Olson and Y. Sun and D. Wen and Kathleen Wortham and Giovanna Antognetti and Anne E Cheung and O. Orozco and L. Yang and V. Bailly and M. Sanicola},
  journal={European journal of cancer},
  year={2011},
  volume={47 11},
  pages={
          1736-46
        }
}
  • R. Kelly, Dian L Olson, +8 authors M. Sanicola
  • Published 2011
  • Biology, Medicine
  • European journal of cancer
  • BIIB015 is an immunoconjugate created for the treatment of solid tumours and is currently in Phase I of clinical evaluation. BIIB015 consists of a humanised monoclonal antibody against the Cripto protein carrying a payload, via a hindered disulphide linker, of the maytansinoid derivative, DM4. Cripto is a GPI-linked protein required for signal transduction of the TGF-beta ligand, Nodal. Cripto has been previously described as an oncogene and fits the classic pattern of an embryonic gene that is… CONTINUE READING
    31 Citations
    Evolving Strategies for Target Selection for Antibody-Drug Conjugates
    • 36
    Linkers Having a Crucial Role in Antibody–Drug Conjugates
    • J. Lu, Feng Jiang, A. Lu, G. Zhang
    • Chemistry, Medicine
    • International journal of molecular sciences
    • 2016
    • 74
    • PDF
    Cripto-1: potential target for cancer immunotherapy?!
    Antibody-Drug Conjugates: Possibilities and Challenges
    • 23
    • Highly Influenced
    • PDF
    Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    • 31

    References

    SHOWING 1-10 OF 36 REFERENCES
    Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
    • 285
    • PDF
    Contribution of linker stability to the activities of anticancer immunoconjugates.
    • 291
    Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
    • 1,161
    • PDF
    Arming antibodies: prospects and challenges for immunoconjugates
    • 939
    Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    • 1,087
    • Highly Influential
    • PDF
    Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
    • 141
    • PDF
    Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    • 433
    • Highly Influential
    • PDF
    Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
    • C. Liu, B. Tadayoni, +9 authors R. Chari
    • Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 1996
    • 198
    • PDF
    Antibody-drug conjugates: targeted drug delivery for cancer.
    • 526
    • Highly Influential